BioNTech’s Oncology Ambitions Fuel Rally Ahead of Pivotal Shareholder Vote

A resurgence in biotech sentiment, driven by sector-wide deal speculation and clinical breakthroughs, is providing a powerful tailwind for BioNTech SE. The company’s shares recently traded near 96 euros, capping a remarkable 30-day rally of nearly 25 percent. This momentum sets the stage for a critical few weeks where the company’s strategic pivot from COVID-19 vaccines to oncology will face decisive tests.

The broader sector provided a significant boost. Inhibrx Biosciences saw its stock surge 39 percent on reports that pharmaceutical giants, including Merck & Co., Merck KGaA, and Japan’s Ono Pharmaceutical, expressed interest in its experimental cancer drug INBRX-106. Analysts estimate the potential value of this single asset could exceed $8 billion. Separately, Kyverna Therapeutics jumped 24 percent after hours on positive data for its CAR-T cell therapy, which met its primary endpoint in a study for Stiff-Person Syndrome.

BioNTech’s own pipeline is contributing to the positive sentiment. In mid-April, the company released encouraging Phase 2 data for its antibody-drug conjugate, trastuzumab pamirtecan (BNT323/DB-1303), in HER2-expressing endometrial cancer. The therapy demonstrated a confirmed objective response rate of 47.9 percent and a median progression-free survival of 8.1 months, with consistent efficacy across all HER2 expression levels. BioNTech and its partner DualityBio aim to file for U.S. approval in 2026, pending regulatory feedback.

This clinical progress is central to a costly and ambitious corporate transformation. Management expects 2026 revenue to decline by approximately a quarter to just over two billion euros as COVID vaccine sales wane. Concurrently, research and development expenses are projected to climb to as much as 2.5 billion euros. To fund this shift, BioNTech is sitting on a massive war chest of roughly 17 billion euros in cash.

That financial buffer may soon be supplemented. The most consequential item on the agenda for the Annual General Meeting on May 15 is a proposal to create new Authorized Capital. This would empower the board to issue nearly 130 million new shares, equivalent to half of the current share capital. The move is designed to secure funding for expensive late-stage cancer trials, with management planning for 15 ongoing Phase 3 studies by year-end.

Should investors sell immediately? Or is it worth buying BioNTech?

The upcoming weeks will deliver crucial operational data points. First, on May 5, BioNTech will report its first-quarter 2026 results and host an update call. Investors will scrutinize the numbers for signs of how the pipeline advances are translating financially and whether annual guidance is reaffirmed.

The shareholder meeting ten days later will then address profound structural changes. Alongside the capital measure, the Supervisory Board is proposed to expand from six to eight members to add expertise in areas like commercialization and clinical development. A profit and loss transfer agreement with a subsidiary is also on the ballot, a tax mechanism allowing future subsidiary profits to be offset against parent company losses.

Leadership is also in transition. Co-founders Ugur Sahin and Özlem Türeci are set to leave the company upon the expiry of their contracts at the end of 2026, moving to manage their new firm. The Supervisory Board has already begun the search for their successors at the helm.

The recent stock performance suggests growing investor confidence in BioNTech’s long-term oncology strategy. With over 25 product candidates in development, the coming month will determine if shareholders are willing to grant the financial authority and endorse the governance changes needed to fully execute it.